When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALLO - Allogene multiple myeloma candidate granted Orphan Drug Designation
Allogene Therapeutics Inc.
The U.S. FDA has granted Orphan Drug Designation to Allogene Therapeutics' (NASDAQ:ALLO) multiple myeloma candidate ALLO-605. The allogeneic CAR T asset is currently in phase 1 targeting B cell maturation antigen (BCMA). ALLO-605 was granted Fast Track status in Q2 2021. Allogene (ALLO) said it would provide an update on its BCMA-targeted programs by the end of the year. Read why Seeking Alpha contributor Terry Chrisomalis argues that Allogene (ALLO) has a big potential in oncology.